EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Towards a scalable bioprocess for rAAV production using a HeLa stable cell line

José Escandell iD, Filipa Moura, Sofia B Carvalho, Ricardo J S Silva iD, Ricardo Correia, Antonio Roldão, Patrícia Gomes-Alves iD, Paula M Alves

Biotechnology and Bioengineering · 2023

DOI: 10.1002/bit.28394 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology and Bioengineering, 2023. Verfasst von José Escandell und 7 weiteren Autor:innen. Beteiligte Einrichtung: iBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal. Hauptthemen laut MEDLINE: Dependovirus, Genetic Vectors. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Horizon 2020 Framework Programme, Fundação para a Ciência e a Tecnologia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The majority of recombinant adeno‐associated viruses (rAAV) approved for clinical use or in clinical trials areproduced by transient transfection using the HEK293 cell line. However, this platform has several manufacturing bottlenecks at commercial scales namely, low product quality (full to empty capsid ratio 3 × 10 11 vg/mL and full to empty capsids ratio (>70%) at 2 L bioreactor scale. Moreover, the established downstream process, based on ion exchange and affinity‐based chromatography, efficiently eliminated process related impurities, including the Adenovirus 5 helper virus required for production with a log reduction value of 9. Overall, we developed a time‐efficient and robust rAAV bioprocess using a stable producer cell line achieving purified rAAV2 yields > 1 × 10 11 vg/mL. This optimized platform may address manufacturing challenges for rAAV based medicines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DependovirusGenetic VectorsHumansHEK293 CellsHeLa CellsTransfection

Stichwörter der Autor:innen

HeLaS3bioprocess developmentcell line developmentdownstream processinggene therapyrecombinant adeno-associated viruses (rAAV)stable cell line

Autor:innen und Institutionen

  • iBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
  • ITQB-NOVA, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.

ORCID-Profile: José Escandell, Ricardo J S Silva, Patrícia Gomes-Alves

Förderung

  • Horizon 2020 Framework Programme
  • Fundação para a Ciência e a Tecnologia

Zitieren

APA

Escandell, J., Moura, F., Carvalho, S. B., Silva, R. J. S., Correia, R., Roldão, A., Gomes-Alves, P., & Alves, P. M. (2023). Towards a scalable bioprocess for rAAV production using a HeLa stable cell line. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28394

Vancouver

Escandell J, Moura F, Carvalho SB, Silva RJS, Correia R, Roldão A, et al. Towards a scalable bioprocess for rAAV production using a HeLa stable cell line. Biotechnology and Bioengineering. 2023. doi:10.1002/bit.28394

BibTeX
@article{Escandell2023,
  author = {Escandell, José and Moura, Filipa and Carvalho, Sofia B and Silva, Ricardo J S and Correia, Ricardo and Roldão, Antonio and Gomes-Alves, Patrícia and Alves, Paula M},
  title = {Towards a scalable bioprocess for rAAV production using a HeLa stable cell line},
  journal = {Biotechnology and Bioengineering},
  year = {2023},
  doi = {10.1002/bit.28394}
}
Kostenlos starten →